Vaccination Prevented Lasting Spleen Damage After Acute Virus Infection in Mice

Mice that cleared an acute viral infection still carried spleen fibrosis and weakened T-cell responses afterward — and prior vaccination completely prevented that damage, according to a study from Pompeu Fabra University (UPF) in Barcelona published in Cell Death & Disease in November 2026.

The finding matters because it challenges a working assumption most clinicians hold without thinking. An acute viral infection is treated as a self-limiting event: virus controlled, symptoms resolved, patient normal. The UPF data say otherwise, at least in the mouse model.

What did the researchers actually find?

The Infection Biology Laboratory at UPF, led by ICREA research professor Andreas Meyerhans, examined mice after they had recovered from acute viral infection. The animals had eliminated the virus. Their immune systems had not returned to baseline.

The team traced the persistent dysfunction to the spleen. As the immune system fought the virus, the organ developed fibrosis — a buildup of scar-like tissue. The arrangement and positioning of immune cells within the spleen became disrupted.

Those structural changes interfered with the cell-to-cell interactions required to activate T cells, the specialized cells of adaptive immunity that recognize and destroy infected cells. The result: mice remained less capable of mounting effective responses to new immune challenges, even though the original infection was fully controlled.

"The infection can be controlled, but that does not necessarily mean that the host has fully recovered," said Dr. Paula Cebollada Rica, first author of the study. "Our findings show that the immune-related consequences of an acute viral infection can persist beyond the period in which the virus is detectable, leaving the animals in an immunocompromised state."

The takeaway: viral clearance and immunologic recovery are not the same event.

Did vaccination change the outcome?

Yes, and completely. The researchers compared vaccinated and unvaccinated animals before infection.

Mice vaccinated before infection developed none of the spleen damage or immune dysfunction seen in the unvaccinated group. Their spleens retained normal structure. Their T cells continued to function at levels comparable to those of mice that had never been infected at all.

"Vaccinated animals did not experience T-cell dysfunction or splenic alterations after recovering from an acute viral infection," Cebollada Rica explained. "This means that vaccination not only prevented the disease resulting from the acute infection but also preserved the immune system's ability to cope with new challenges."

In plain terms: in this model, vaccination protected not just against the disease, but against the hidden cost of fighting it.

What are the implications for practice and public health?

The work is a mouse study. It does not establish that the same post-infection splenic changes occur in humans, dogs, cattle, or any other species, and the authors say so explicitly. What it does is open a research question with consequences across species: whether apparently resolved viral infections leave patients — companion or food animal — in a measurably immunocompromised state, and whether vaccination prevents it.

For practitioners, the immediate relevance is in the conversation, not the protocol. The study adds an evidence-based argument for completing vaccination schedules in animals that will face subsequent pathogen exposure: the benefit may extend beyond disease prevention to preservation of immune competence itself.

The public health dimension is explicit in the authors' framing. The research arrives as vaccination policy is increasingly shaped by political decisions, and the authors stress that scientific evidence should inform how the full consequences of infection — visible and hidden — are weighed when policy choices could undermine coordinated prevention efforts.

"The benefits of vaccination highlighted by this research are important not only for healthcare, but also for how we communicate the value of vaccination to the population at large," Meyerhans said. "Put simply, vaccines provide strong health benefits at a relatively low cost to society."

The study, titled "Temporal lymphatic tissue destruction and impairment of de novo T cell responses after an acute virus infection," carries a 20-author team spanning UPF and collaborating institutions. Next steps will hinge on whether comparable persistent lymphoid-tissue damage can be demonstrated after natural viral infections in other species — work that, if confirmed, would sharpen the case for vaccination well beyond the prevention of acute disease.